Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Recruiting

Phase 2

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT TrialComparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05773274

Conditions

Metastatic Midgut Neuroendocrine Tumor

Metastatic Midgut Neuroendocrine Tumor G1

Metastatic Midgut Neuroendocrine Tumor G2

Unresectable Midgut Neuroendocrine Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Everolimus

Lutetium Lu 177 Dotatate

Quality-of-Life Assessment

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-02. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-03-26.